Does the Serous Component Rate Affect Survival in Patients with Mixed Type Endometrium Cancer?
DOI:
https://doi.org/10.58600/eurjther2802Keywords:
endometrial cancer, mixed type, survivalAbstract
Objective: This research aimed to investigate whether the proportion of the serous carcinoma component influences the prognosis of patients diagnosed with mixed-type endometrial carcinoma.
Methods: Based on the relative percentage of the serous component, patients were grouped into two categories: ≤50% and >50%. These groups were analyzed and compared with respect to demographic characteristics (age, body mass index, and parity), and histopathological features (grade, level of myometrial invasion, lymphovascular space invasion, tumor size, and FIGO stage). Cox regression and Kaplan–Meier survival analyses were used for the evaluation of overall survival (OS), disease-free survival (DFS), recurrence, and mortality rates.
Results: Individuals with a serous component exceeding 50% had significantly reduced DFS and OS (DFS: 42.9 ± 25.9 vs. 60.2 ± 25.9 months, p = 0.04; OS: 47.9 ± 24.8 vs. 68.7 ± 20.5 months, p = 0.007). Multivariate analysis identified age, deep myometrial invasion, and serous predominance (>50%) as independent predictors of poorer DFS and OS (p < 0.05). Tumor size and lymphovascular space invasion (LVSI) did not have statistically significant correlations with survival outcomes.
Conclusion: Although rare, mixed-type endometrial carcinoma with a dominant serous component appears to exhibit more aggressive behavior and poorer survival. The proportion of serous histology should be regarded as a critical prognostic indicator during clinical assessment and treatment planning.
References
Lax SF (2016) Neues in der WHO-Classification 2014 der Tumoren des Corpus uteri [New features in the 2014 WHO classification of uterine neoplasms]. Pathologe. 37(6):500-511. https://doi.org/10.1007/s00292-016-0230-4
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, et al. (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74(3):229-263. https://doi.org/10.3322/caac.21834
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, et al. (2016) ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 27(1):16-41. https://doi.org/10.1093/annonc/mdv484
Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 15(1):10-17. https://doi.org/10.1016/0090-8258(83)90111-7
Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, et al. (2013) Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 129(2):277-284. https://doi.org/10.1016/j.ygyno.2013.02.023
Matrai C, Motanagh S, Mirabelli S, Ma L, He B, et al. (2020) Molecular Profiles of Mixed Endometrial Carcinoma. Am J Surg Pathol. 44(8):1104-1111. https://doi.org/10.1097/pas.0000000000001519
Fader AN, Starks D, Gehrig PA, Secord AA, Frasure HE, et al. (2009) UPSC Consortium. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC) Gynecol Oncol. 115(2):244-248. https://doi.org/10.1016/j.ygyno.2009.07.030
Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R (1982) Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 6(2):93-108. https://doi.org/10.1097/00000478-198203000-00002
Pappa C, Le Thanh V, Smyth SL, Zouridis A, Kashif A, et al. (2023) Mixed Endometrial Epithelial Carcinoma: Epidemiology, Treatment and Survival Rates-A 10-Year Retrospective Cohort Study from a Single Institution. J Clin Med. 12(19):6373. https://doi.org/10.3390/jcm12196373
Williams KE, Waters ED, Woolas RP, Hammond IG, McCartney AJ (1994) Mixed serous-endometrioid carcinoma of the uterus: pathologic and cytopathologic analysis of a high-risk endometrial carcinoma. Int J Gynecol Cancer. 4(1):7-18. https://doi.org/10.1046/j.1525-1438.1994.04010007.x
Duong LM, Wilson RJ, Ajani UA, Singh SD, Eheman CR (2011) Trends in endometrial cancer incidence rates in the United States, 1999-2006. J Womens Health (Larchmt). 20(8):1157-1163. https://doi.org/10.1089/jwh.2010.2529
Kaban A, Topuz S, Sozen H, Salihoglu Y (2019) Does the Increased Rate of Serous Component (≤25% vs. >25%) Increase Recurrence in Endometrial Cancer With Serous Plus Endometrioid Histology?. J Obstet Gynaecol Can. 41(2):160-165. https://doi.org/10.1016/j.jogc.2018.03.002
Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, et al. (2023) Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee. FIGO staging of endometrial cancer: 2023. J Gynecol Oncol. 34(5):e85. https://doi.org/10.3802/jgo.2023.34.e85
Downloads
Published
How to Cite
License
Copyright (c) 2025 Gökşen Görgülü, Emel Doğan Özdaş, Erol Özdaş, Ayşe Taş, Esin Kasap, Tuğba Karadeniz, Muzaffer Sancı
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
